RCT 46 hospitalized patients with moderate COVID-19 pneumonia, 24 treated wth N-acetylcysteine, showing significantly shorter hospitalization with treatment. NAC 1,200 – 1,500mg/day intravenously.
hospitalization time, 15.4% lower, relative time 0.85, p < 0.001, treatment 24, control 22.
|
relative improvement in lung Ct, 50.7% better, RR 0.49, p < 0.001, treatment 24, control 22.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Gaynitdinova et al., 2/19/2021, Randomized Controlled Trial, Russia, Europe, peer-reviewed, 6 authors, average treatment delay 7.0 days.